Open AccessLong-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Author(s) -
Linda B. Piller,
Sarah Baraniuk,
Lara M. Simpson,
William C. Cushman,
Barry M. Massie,
Paula T. Einhorn,
Suzanne Oparil,
Charles E. Ford,
James F. Graumlich,
Richard A. Dart,
David C. Parish,
Tamrat M. Retta,
Aloysius B. Cuyjet,
Syed Z. A. Jafri,
Curt D. Furberg,
Mohammad G. Saklayen,
Udho Thadani,
Jeffrey L. Probstfield,
Barry R. Davis
Publication year - 2011
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.110.012575
Subject(s) - medicine , lisinopril , chlorthalidone , amlodipine , heart failure , hazard ratio , randomized controlled trial , cardiology , ejection fraction , blood pressure , confidence interval , angiotensin converting enzyme
In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, practice-based, active-control, comparative effectiveness trial in high-risk hypertensive participants, risk of new-onset heart failure (HF) was higher in the amlodipine (2.5-10 mg/d) and lisinopril (10-40 mg/d) arms compared with the chlorthalidone (12.5-25 mg/d) arm. Similar to other studies, mortality rates following new-onset HF were very high (≥50% at 5 years), and were similar across randomized treatment arms. After the randomized phase of the trial ended in 2002, outcomes were determined from administrative databases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom